cu-67 dotatate

Cu-67 dotatate is a radiopharmaceutical composed of copper-67 (^67Cu), a radioactive isotope, chelated to the somatostatin analog dotatate (Tyr3-octreotate) using a chelator like NODAGA. It targets somatostatin receptor subtype 2 (SSTR2), which is highly expressed on neuroendocrine tumors (NETs). Upon intravenous administration, the conjugate binds to SSTR2-expressing tumor cells and delivers localized beta radiation from ^67Cu, leading to cellular damage and tumor regression. ^67Cu also emits gamma rays enabling SPECT imaging and dosimetry. Cu-67 dotatate is under preclinical and early clinical evaluation as a theranostic agent for the treatment and imaging of SSTR2-positive cancers, with animal studies demonstrating inhibition of tumor growth and increased survival in SSTR2-positive tumor models[1][5].

Other names

copper-67 dotatatecopper67 dotatatecopper 67 dotatate^67Cu-dotatate^67Cu-labeled NODAGA-TATE[^67Cu]Cu-NODAGA-TATE